Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects

← catalyst calendar

NCT05156398 · readout in 1,927 d

Sponsored by Pfizer (industry) · PFE — their whole pipeline →.

Phase

Phase 3

Status

Recruiting

Study type

Interventional

Design

Randomized · Quadruple · Prevention

Enrollment

640estimated

Sites

Countries

Canada, France, Italy +4

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2022-02-28

actual

When the study began enrolling

Primary completion

2031-11-29

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2032-11-27

estimated

The whole study's end, after follow-up

First posted

2021-12-14

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-29

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Migraine

Interventions

Drug: Rimegepant — also filed as BHV3000
Drug: Placebo — also filed as Matching Placebo

Primary outcome

what the primary-completion date above is the date OF

Change from baseline in the mean number of migraine days per month as measured over the 12-week double-blind phase of the study in adolescents with episodic migraine

measured 3 months (12 weeks)

Publications

PMID 41235617 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed